What is the debt of Novavax this year?
Novavax has a debt level of -339.42 USD this year.
Novavax Debt 2024
Novavax Debt
-339.42 USD
Ticker
NVAX
ISIN
US6700024010
WKN
A2PKMZ
In 2024, Novavax's total debt was -339.42 USD, a -56.88% change from the -787.1 USD total debt recorded in the previous year.
Novavax Aktienanalyse
What does Novavax do?
Novavax Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines and products for the treatment of infectious diseases. The company was founded in 1987 in Maryland, USA, and has since relocated its headquarters to Gaithersburg, Maryland. Novavax is a pioneer in vaccine technology. The company's business model is based on the development of vaccines for diseases such as malaria, Zika, RSV, and COVID-19. Novavax uses the latest technology and methods to ensure the highest efficacy and safety of its vaccines. By licensing its own technologies and licenses, the company has significantly increased its reach and effectiveness, establishing successful partnerships with institutions such as the Bill and Melinda Gates Foundation and the US Department of Defense. The different divisions of the company are focused on the development of vaccines and antiviral therapies. Novavax is involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Currently, Novavax is conducting studies in the field of Respiratory Syncytial Virus (RSV) vaccination. The RSV program is Novavax's oldest program, launched in 1995, and the company has developed several vaccine candidates. A recent Phase III trial of an RSV vaccine candidate for the prevention of RSV infections in pregnant women did not meet its goals. However, it is a key position in vaccine development, allowing the company to focus on the development of vaccines against other infectious diseases. Novavax also has an ongoing research program focused on developing a COVID-19 vaccine candidate based on a protein called Nanoparticle Spike Protein (NVX-CoV2373) expressed in insect cells. A major advantage of this program is that it allows for faster manufacture of millions of doses with high throughput and has consistently shown positive results in clinical studies. The company has also developed a revolutionary technology called Matrix-M, which is used in its vaccines to enhance the immune response and activity against the vaccine. It is an adjuvant technology that stimulates the body to respond to a vaccine and achieve higher immunity against the pathogen. Novavax has a number of vaccine candidates in clinical development, including vaccines against malaria, influenza, and human papillomavirus (HPV), as well as an antiviral therapy for the treatment of RSV. These programs are still in the early stages of development, but the company is confident that it will be successful in the future. Overall, Novavax is a company specializing in the development of innovative vaccines and antiviral therapies for the treatment of infectious diseases. With a focus on safety, efficacy, and innovation, the company has achieved a leading position in vaccine technology and has become a key player in the global health landscape. Answer: Novavax is a biopharmaceutical company that specializes in developing and marketing innovative vaccines and products for treating infectious diseases. It was founded in 1987 in Maryland, USA, and focuses on developing vaccines against diseases like malaria, Zika, RSV, and COVID-19. The company uses advanced technology and methods to ensure the effectiveness and safety of its vaccines. It has partnerships with institutions like the Bill and Melinda Gates Foundation and the US Department of Defense. Novavax is also involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Its oldest program is focused on developing an RSV vaccine, and it also has a program focused on developing a COVID-19 vaccine. Novavax has developed a technology called Matrix-M, which enhances the immune response to vaccines. It also has vaccine candidates in development for malaria, influenza, and HPV, as well as an antiviral therapy for RSV. Overall, Novavax is a leading company in vaccine technology and aims to develop effective and innovative vaccines and antiviral therapies for infectious diseases. Novavax ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Novavax's Debt Structure
Novavax's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Novavax's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Novavax’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Novavax’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Novavax stock
What was the debt of Novavax compared to the previous year?
The debt of Novavax has increased by -56.88% compared to the previous year dropped.
What are the consequences of high debt for investors in Novavax?
High debt can pose a risk for investors of Novavax, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Novavax?
Low debt means that Novavax has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Novavax affect the company?
An increase in debt of Novavax can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Novavax affect the company?
A reduction in debt of Novavax can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Novavax?
Some factors that can influence the debt of Novavax include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Novavax so important for investors?
The debts of Novavax are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Novavax take to change the debt?
To change the debt, Novavax can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Novavax pay?
Over the past 12 months, Novavax paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novavax is expected to pay a dividend of 0 USD.
What is the dividend yield of Novavax?
The current dividend yield of Novavax is .
When does Novavax pay dividends?
Novavax pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novavax?
Novavax paid dividends every year for the past 0 years.
What is the dividend of Novavax?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novavax located?
Novavax is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novavax kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novavax from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.
When did Novavax pay the last dividend?
The last dividend was paid out on 11/18/2024.
What was the dividend of Novavax in the year 2023?
In the year 2023, Novavax distributed 0 USD as dividends.
In which currency does Novavax pay out the dividend?
The dividends of Novavax are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Novavax stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital
Andere Kennzahlen von Novavax
Our stock analysis for Novavax Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novavax Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
